As previously reported, Leerink downgraded Myriad Genetics (MYGN) to Market Perform from Outperform with a price target of $21, down from $30. Despite the remarkable transformation over the last 4 years under CEO Paul Diaz, where Myriad returned to profitability and growth, the market backdrop from both reimbursement and competition is suddenly worsening, the firm says. With further competitive pressures now rising in 2025 for its Prolaris prostate cancer assay, delays in addressing the GeneSight coverage by UnitedHealth (UNH), rising risk for potential Medicaid cuts, limited further upside from Invitae’s (NVTA) disruption in the hereditary cancer testing market, CGP remaining competitive, and MRD a 2026 story, Leerink sees minimal avenues for growth in the near-to-medium term.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MYGN:
- Myriad Genetics downgraded to Market Perform from Outperform at Leerink
- Myriad Genetics Settles Shareholder Lawsuits with Reforms
- Myriad announces Prequel Prenatal Screening can be performed at 8 weeks
- Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley
- Myriad Genetics price target lowered to $24 from $34 at Scotiabank
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
